Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia

Keyphrases

• B Cells 100%
• Chronic Lymphocytic Leukemia 100%
• Bendamustine 100%
• Lymphoid Malignancies 100%
• Chlorambucil 26%
• Chemotherapy 20%
• Adverse Events 20%
• Fludarabine 20%
• Quality of Life 13%
• Meta-analysis 13%
• Cyclophosphamide 13%
• Randomized Controlled Trial 13%
• Chemotherapy Regimen 13%
• Follicular Lymphoma 13%
• Survival Benefit 13%
• Progression-free Survival 13%
• Mantle Cell Lymphoma 13%
• Rituximab 13%
• Progressive Disease 13%
• Small Lymphocytic Lymphoma 13%
• Adult Patients 6%
• Advanced Stage 6%
• Confidence Interval 6%
• MEDLINE 6%
• Embase 6%
• Search Methods 6%
• Disease Course 6%
• Prednisone 6%
• Cochrane Library 6%
• Risk Ratio 6%
• Disease Control 6%
• Selection Criteria 6%
• Extracted Data 6%
• Response Rate 6%
• Conference Proceedings 6%
• Hazard Ratio 6%
• Randomized Clinical Trial 6%
• Doxorubicin 6%
• Lymphoma 6%
• Overall Survival 6%
• First Author 6%
• Hazard Risk 6%
• Relapsed Disease 6%
• Effects on Survival 6%
• Cochrane Central Register of Controlled Trials 6%
• Trial Data 6%
• Slow Growth 6%
• Induction Therapy 6%
• Clinical Heterogeneity 6%
• Overall Survival of Patients 6%
• Data Reporting 6%
• Issue 2 6%
• Ongoing Trials 6%
• Marginal Zone Lymphoma 6%
• Selective Reporting 6%
• Lymphoplasmacytic Lymphoma 6%
• Indolent Lymphoma 6%

Medicine and Dentistry

• B Cell 100%
• B-Cell Chronic Lymphocytic Leukemia 100%
• Lymphoma 100%
• Bendamustine 100%
• Chlorambucil 26%
• Lymphocytic Lymphoma 26%
• Adverse Event 20%
• Fludarabine 20%
• Meta-Analysis 13%
• Quality of Life 13%
• Randomized Controlled Trial 13%
• Cyclophosphamide 13%
• Overall Survival 13%
• Follicular Lymphoma 13%
• Progression Free Survival 13%
• Mantle Cell Lymphoma 13%
• Progressive Disease 13%
• Rituximab 13%
• Chemotherapy 13%
• Systematic Review 6%
• Recurrent Disease 6%
• Prednisone 6%
• Immunotherapy 6%
• Randomized Clinical Trial 6%
• Disease Course 6%
• Vincristine 6%
• Hazard Ratio 6%
• Doxorubicin 6%
• MALT Lymphoma 6%
• CHOP 6%
• Waldenström's Macroglobulinemia 6%
• Diseases 6%
• Chemotherapy 6%

Pharmacology, Toxicology and Pharmaceutical Science

• Chronic Lymphatic Leukemia 100%
• Bendamustine 100%
• Lymphoma 100%
• Chemotherapy 33%
• Chlorambucil 26%
• Lymphocytic Lymphoma 26%
• Adverse Event 20%
• Fludarabine 20%
• Cyclophosphamide 13%
• Randomized Controlled Trial 13%
• Overall Survival 13%
• Progression Free Survival 13%
• Mantle Cell Lymphoma 13%
• Rituximab 13%
• Follicular Lymphoma 13%
• Diseases 13%
• Prednisone 6%
• Immunotherapy 6%
• Randomized Clinical Trial 6%
• Disease Course 6%
• Doxorubicin 6%
• Vincristine 6%
• Waldenstroem macroglobulinemia 6%
• Marginal Zone Lymphoma 6%